News and Events
Solutions for Detection of Apoptosis in Oncology Xenograft Models
At DiaPharma, we specialize in biomarker assays designed to advance oncology research. One of the hallmarks of cancer is the evasion of apoptosis by tumor cells—making the detection of cellular death, especially apoptosis, a critical readout in the evaluation of anti-cancer therapies.
Xenograft models are widely used in oncology research to study cancer therapies in vivo. However, methods for evaluating the effect of potential drug candidates on tumor growth—such as volume measurements, imaging, or immunohistochemical staining—are often imprecise, expensive, technically demanding, or require sacrificing the xenograft host.
An alternative is the M30 Apoptosense® ELISA*.
What is the M30 Apoptosense® ELISA?
This blood-based biomarker assay utilizes the M30® antibody which specifically detects a caspase-cleaved fragment of cytokeratin 18 (CK18), a cytoskeletal protein expressed in epithelial cells and cleaved by caspases early during apoptosis. The cleaved CK18 fragment (ccK18) is released into the bloodstream, and its concentration in serum or plasma measured with the M30 Apoptosense® ELISA correlates with the extent of epithelial cell apoptosis.
Why choose the M30 Apoptosense® ELISA for use with your xenograft model?
● The M30® antibody is highly specific for human ccK18 and does not cross-react with murine proteins, enabling precise detection of apoptosis of human tumor cells with xenograft models.
● Minimally invasive blood sampling allows for longitudinal assessment of treatment response.
● The assay provides sensitive, quantitative measurements to evaluate dose- and time-dependent effects of potential drug candidates.
● Incorporating the M30® biomarker offers a robust, translational tool to strengthen efficacy assessments — particularly valuable for bridging preclinical findings to clinical applications.
We would be happy to provide more detailed information tailored to your research. Please don’t hesitate to reach out to our Scientists or your local DiaPharma Territory Manager.
*For research use only in US and Canada. Not for use in diagnostic procedures.
-
Hypercoagulation During Sickle Cell Disease
Posted: May 19, 2021
Hypercoagulation During Sickle Cell Disease Contributed by Abi Kasberg, PhD Sickle cell disease (SCD) is a genetic hemoglobin disease that disrupts the ability of red blood cells (RBCs) to deliver oxygen throughout the body. RBCs are normally round and flexible, which allows them to flow easily through vasculature. However, in SCD, RBCs are crescent-shaped due…
-
Lupus Anticoagulants/Antiphospholipid Antibodies/Antiphospholipid Antibody Syndrome – Part 2
Posted: April 29, 2021
CLOT CLUB David L. McGlasson, MS, MLS(ASCP) Lupus Anticoagulants/Antiphospholipid Antibodies/Antiphospholipid Antibody Syndrome Part II Testing for Antiphospholipid Antibody Syndrome Platelet-Poor Plasma (PPP) The quality of the patient’s PPP greatly affects the integrity of the testing. To obtain PPP, the capped citrated specimen is centrifuged at room temperature for at least 15 minutes at 1500–2500 Xg.…
-
Lupus Anticoagulants/Antiphospholipid Antibodies/Antiphospholipid Antibody Syndrome – Part 1
Posted: March 29, 2021
CLOT CLUB David L. McGlasson, MS, MLS(ASCP) Lupus Anticoagulants/Antiphospholipid Antibodies/Antiphospholipid Antibody Syndrome Part I The late Douglas A. Triplett, MD, PhD, who was a colossal figure in the field of Coagulation, paraphrased Winston Churchill in describing a lupus anticoagulant/antiphospholipid antibody as: “a riddle, wrapped in a mystery, inside an enigma.” In other words, a difficult…
-
Detecting Hemoglobin Variants during Sickle Cell Disease Research: Which Method is Best?
Posted: March 15, 2021
– Contributed by Abi Kasberg, PhD Hemoglobins are protein molecules found in red blood cells (RBCs) that functionally transport oxygen from the lungs to the cells of the body and to shuttle carbon dioxide back to the lungs. Hemoglobins also play important roles in maintaining RBC shape by dynamically changing conformation through binding oxygen.…
-
Insights into an Imbalanced vWF antigen to ADAMTS-13 activity ratio in COVID-19
Posted: February 16, 2021
-Contributed by Abi Kasberg, PhD One of the many complicated outcomes associated with severe cases of COVID-19 is the high occurrence of thrombotic and microthrombotic events. SARS-CoV-2-induced endothelial injury drives elevated inflammatory responses that promote dysregulated coagulation systems, in a condition named COVID-19-associated coagulopathy (CAC). The severity of CAC is associated with the onset of…
-
THSNA 2020 Virtual Meeting
Posted: December 8, 2020
David L. McGlasson, MS, MLS(ASCP) The recent THSNA meeting that was supposed to held in Chicago, IL from October 27-30, 2020 was held in a virtual meeting setting. This seems to be the theme this year for all of the professional events that have been affected by the world-wide COVID-19 pandemic. The one thing I…
-
Proposed Mechanisms of Platelet Dynamics during COVID-19
Posted: October 2, 2020
– Contributed by Abi Kasberg, PhD The novel coronavirus worldwide pandemic of 2020 is infecting and claiming lives at a rapid rate. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe acute respiratory distress and multiple system organ failure in a disease called COVID-19. SARS-CoV-2 enters cells by endocytosis through binding…
-
Activated Protein C Resistance (APCR), Factor V Leiden (FVL), and a Case Report of a Family with the presence of FVL over 5 generations.
Posted: September 25, 2020
Activated Protein C Resistance (APCR), Factor V Leiden (FVL), and a Case Report of a Family with the presence of FVL over 5 generations. Prior to 1992 the special coagulation laboratory performed testing on three inherited thrombotic risk factors. Antithrombin (formerly known as ATIII), Protein C, and Protein S deficiencies were implicated in venous thromboembolism…
-
COVID-19 – Frequently Asked Questions
Posted: September 3, 2020
– Contributed by Abi Kasberg, PhD The global pandemic caused by the coronavirus SARS-CoV-2 has captured the attention of researchers, medical professionals, governments, and nearly everyone worldwide. The scientific and medical communities are forming collaborations, gathering data, developing therapeutics, and communicating findings at a swift speed. Indeed, it can be a challenge to stay informed…
-
ISTH 2020
Posted: August 18, 2020
The recent ISTH 2020 meeting that was supposed to be held in Milan, Italy was still a success even in a virtual setting. As always, the topics were extremely informative. The addition of ISTH TV was an innovative way of presenting new information in a roundtable format with top members of the coagulation community. The…